Medical research and development contract for army sttr phase II proposal no. A2-9471 titled development and testing of a military-grade wearable transcutaneous auricular neurostimulation device to…
Ended Definitive Contract Awarded Last action
- Contract number
- HT942523C0042
- Awardee
-
Spark Biomedical Inc. UEI KUGZUDSCWQK5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,149,775
Award facts
- Opportunity
-
- HQ003420R2ADB Solicitation number
- Contract value 100% obligated
- $1,149,775.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Friendswood, TX 77546, USA
- Research
- STTR Phase II
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $575,086 | |
| Original award | $574,689 |
About this award
The Defense Health Agency awarded a Small Business Technology Transfer (STTR) Phase II contract valued at $1.15 million to Spark Biomedical Inc., a small disadvantaged business specializing in neuromodulation medical devices. Under this firm fixed-price definitive contract (Proposal No. A2-9471), Spark Biomedical will develop and test a military-grade wearable transcutaneous auricular neurostimulation device designed to restore performance in military personnel experiencing acute stress reactions. The contract, set aside for small businesses, is scheduled for completion by November 13, 2025, with performance conducted in Friendswood, Texas.
This STTR Phase II award represents a continuation of Spark Biomedical's earlier Phase I work with the Defense Health Agency and Army Medical Command to advance non-invasive neurological intervention technologies for military applications. The company's expertise in transcutaneous auricular neurostimulation—a technique that delivers electrical stimulation to auricular nerves—directly addresses the Army's need for innovative solutions to enhance soldier resilience and performance in high-stress operational environments. Spark Biomedical's prior federal research funding and collaborations with academic institutions on neurostimulation therapies for substance withdrawal and neurological conditions position the company to successfully deliver a clinically validated, deployable device for military personnel.
Description
Medical research and development contract for army sttr phase II proposal no. A2-9471 titled development and testing of a military-grade wearable transcutaneous auricular neurostimulation device to restore performance after acute stress reaction.
Quick answers
Who was awarded contract HT942523C0042?
HT942523C0042 was awarded to Spark Biomedical Inc. by Defense Health Agency (Department of Defense) on July 14, 2023.
How much is contract HT942523C0042 worth?
The government has obligated $1,149,775 on HT942523C0042.
Was contract HT942523C0042 competed?
The extent of competition for HT942523C0042 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award